The journal Experimental and Molecular Pathology recently published a Letter to the Editor written by CBM2 faculty member Dr. David Kaufman titled, “The need for rapid therapeutic efficacy testing for cancer therapy.”

In the letter, Kaufman suggests that cancer patients would be better served if, using precision medicine, they could spend less time receiving ineffective treatments from resistance to therapy. It would be desirable if there was a way to determine if a therapy was effective or not, and to have that determination made in hours rather than weeks or months. He says, “The recent advent of liquid biopsies for cancer care holds the prospect for facilitating such a functional analysis of the efficacy of cancer therapy.”

Read Dr. Kaufman’s letter to the editor here: Experimental and Molecular Pathology 113 (2020) 104382